RTC-30 |
| Katalog-Nr.GC37567 |
RTC-30 ist ein optimiertes Phenothiazin mit krebshemmender Wirkung. RTC-30 enthÄlt einen hydroxylierten Linker (N), der eine erhÖhte orale BioverfÜgbarkeit verleiht.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1423077-95-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
RTC-30 is an optimized phenothiazine with anti-cancer potency. RTC-30 contains a hydroxylated linker (N) that confers increased oral bioavailability[1].
RTC-30 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 15 μM[1]. Cell Viability Assay[1] Cell Line: H1650 lung adenocarcinoma cells
[1]. Kastrinsky DB, et al. Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *